Sharp Therapeutics (Biotechnology) Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • SHRX

Stock Symbol

  • Share Price
  • $0.98
  • (As of Monday Closing)

Sharp Therapeutics (Biotechnology) General Information

Description

Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.

Contact Information

Website
www.sharptx.com
Formerly Known As
Sharp Edge Technologies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2403 Sidney Street
  • Suite 264
  • Pittsburgh, PA 15203
  • United States
+1 (412)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
TSX
Vertical(s)
Corporate Office
  • 2403 Sidney Street
  • Suite 264
  • Pittsburgh, PA 15203
  • United States
+1 (412)

Sharp Therapeutics (Biotechnology) Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sharp Therapeutics (Biotechnology) Stock Performance

As of 21-Sep-2026, Sharp Therapeutics (Biotechnology)’s stock price is $0.98. Its current market cap is $30.9M with 31.6M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.98 $0.99 $0.16 - $3.55 $30.9M 31.6M 1.4K -$0.17

Sharp Therapeutics (Biotechnology) Financials Summary

As of 30-Jun-2026, Sharp Therapeutics (Biotechnology) has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 19,572 54,184
Revenue 0 0 0 0
EBITDA (4,924) (5,909) (2,989) (3,276)
Net Income (5,181) (6,174) (3,261) (3,565)
Total Assets 1,042 1,952 4,554 1,546
Total Debt 2,258 1,283 1,316 8,419
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sharp Therapeutics (Biotechnology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sharp Therapeutics (Biotechnology)‘s full profile, request access.

Request a free trial

Sharp Therapeutics (Biotechnology) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Sharp Therapeutics (Biotechnology)‘s full profile, request access.

Request a free trial

Sharp Therapeutics (Biotechnology) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It h
Biotechnology
Pittsburgh, PA
5 As of 2026

Lebanon, NH
 

Zug, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sharp Therapeutics (Biotechnology) Competitors (49)

One of Sharp Therapeutics (Biotechnology)’s 49 competitors is Adimab, a Venture Capital-Backed company based in Lebanon, NH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adimab Venture Capital-Backed Lebanon, NH
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Intellia Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 49 competitors. Get the full list »

Sharp Therapeutics (Biotechnology) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sharp Therapeutics (Biotechnology) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sharp Therapeutics (Biotechnology)‘s full profile, request access.

Request a free trial

Sharp Therapeutics (Biotechnology) ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Diversified Financials

Industry

Rank

Percentile

Asset Management and Custody Services

Subindustry

Rank

Percentile

To view Sharp Therapeutics (Biotechnology)’s complete esg history, request access »

Sharp Therapeutics (Biotechnology) FAQs

  • When was Sharp Therapeutics (Biotechnology) founded?

    Sharp Therapeutics (Biotechnology) was founded in 2010.

  • Where is Sharp Therapeutics (Biotechnology) headquartered?

    Sharp Therapeutics (Biotechnology) is headquartered in Pittsburgh, PA.

  • What is the size of Sharp Therapeutics (Biotechnology)?

    Sharp Therapeutics (Biotechnology) has 5 total employees.

  • What industry is Sharp Therapeutics (Biotechnology) in?

    Sharp Therapeutics (Biotechnology)’s primary industry is Biotechnology.

  • Is Sharp Therapeutics (Biotechnology) a private or public company?

    Sharp Therapeutics (Biotechnology) is a Public company.

  • What is Sharp Therapeutics (Biotechnology)’s stock symbol?

    The ticker symbol for Sharp Therapeutics (Biotechnology) is SHRX.

  • What is the current stock price of Sharp Therapeutics (Biotechnology)?

    As of 21-Sep-2026 the stock price of Sharp Therapeutics (Biotechnology) is $0.98.

  • What is the current market cap of Sharp Therapeutics (Biotechnology)?

    The current market capitalization of Sharp Therapeutics (Biotechnology) is $30.9M.

  • Who are Sharp Therapeutics (Biotechnology)’s competitors?

    Adimab, CRISPR Therapeutics, Immunocore Holdings, Adaptimmune Therapeutics, and Intellia Therapeutics are some of the 49 competitors of Sharp Therapeutics (Biotechnology).

  • What is Sharp Therapeutics (Biotechnology)’s annual earnings per share (EPS)?

    Sharp Therapeutics (Biotechnology)’s EPS for 12 months was -$0.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process